University of Cincincati




DOCKET NUMBER PETITION RULE PRM 35-9 (54 FR 38239) University of Cincinnati Hospital

234 Goodman Street Cincinnati, Ohio 45267-0577 \*89 NOV -8 A 9 :22

October 13. 1989



Eugene L. Saenger Radioisotope Laboratory Mail Location #577 TELEPHONE (513) 558-4282



Secretary of the Commission Nuclear Regulatory Commission Docketing and Service Branch Docket (PRN-35-9 Region III 799 Roosevelt Road Glen Ellyn, Illinois 60137

Dear Sir:

I am writing to support, with all my ability, the Petition for Rule Making of the American College of Nuclear Physicians/Society of Nuclear Medicine. I am a physician practicing Nuclear Medicine at the Jewish Hospital and University Hospital. Cincinnati. Ohio and am perturbed by the recently revised 10 CFR 35 regulations governing the medical use of by-product material. They are definitely an impediment to my practice of Nuclear Medicine! As new uses for radiopharmaceuticals become available these do not always appear on the manufacturers' label and yet the FDA has permitted us to use these to enhance patient diagnosis. as for example when sulfur colloid was first employed for gastric emptying studies. The NRC should recognize that the FDA does allow other clinical uses of approved drugs than those that appear on the label which was never meant to prohi'it physicians from deviating from it for appropriate indications. Manufacturers may wait years to revise a package insert because it is costly and they know that clinical indications for new uses for their products have appeared in literature and are quite clear.

Currently the regulatory provisions in Part 35 do not allow practices which are legal under FDA regulations and those of the State of Ohio. Therefore, you are interfering with my practice of Medicine, which does not seem to fit with your own medical policy statement against such interference. I do not believe it appropriate for the NRC to regulate radiopharmaceutical use. I rely on the State of Ohio and the FDA for this.

I do support your regulating more tightly the therapeutic use of iodine-131 to avoid misadministrations in this area but doing this should in no way impinge upon the practice of Radiopharmacy.

Cordially.

Edward B. filberstern

Edward B. Silberstein, M.D. Professor of Medicine and Radiology

EBS/snm

#5

8911150235 891013 PDR PRM 35-9 PDR D210

OCT 2 7 10

Patient Care • Education • Research • Community Service An affirmative action/equal opportunity institution